

## Supplementary Material

### **Childhood infection, antibiotic exposure and subsequent metabolic risk in adolescent and young adult Aboriginal Australians: practical implications**

*Sandra Campbell<sup>A,D,E</sup>, Ella Tracey<sup>B</sup>, Ruth Fagan<sup>C</sup>, Kingsley Pearson<sup>C</sup>, Fintan Thompson<sup>A</sup>, Robyn McDermott<sup>A,\*</sup> and Malcolm McDonald<sup>A,\*</sup>*

<sup>A</sup>Centre for Chronic Disease Prevention, James Cook University, McGregor Road, Smithfield, Qld 4870, Australia.

<sup>B</sup>College of Medicine and Dentistry, James Cook University, McGregor Road, Smithfield, Qld 4878, Australia.

<sup>C</sup>Gurriny Yealamucka Health Service Aboriginal Corporation, Bukki Road, Yarrabah, Qld 4871, Australia.

<sup>D</sup>Present address: Centre for Indigenous Health Equity Research, Central Queensland University, Level 3 Cairns Square, cnr Abbott and Shields Streets, Cairns, Qld 4870, Australia.

<sup>E</sup>Corresponding author. Email: [s.campbell@cqu.edu.au](mailto:s.campbell@cqu.edu.au)

\*The last two authors are joint senior authors.

**Table S1. Number of presentations with antibiotics prescribed in each age group from 0–5 years, recorded reason for prescription, and range of illness frequency per person (*n* = 313)**

	Total presentations 0–5 years	0–6 months Number of individuals <i>n</i> (%) (range)	7–12months Number of individuals <i>n</i> (%) (range)	1–2 years Number of individuals <i>n</i> (%) (range)	2–5 years Number of individuals <i>n</i> (%) (range)
Ear	382	46 (14.7) (1–2)	74 (23.6) (1–3)	101 (32.3) (1–4)	99 (31.6) (1–4)
Lower respiratory tract	332	70 (22.4) (1–2)	75 (24) (1–3)	66 (21.1) (1–4)	64 (20.4) (1–4)
Skin and soft tissue	322	50 (15.9) (1–4)	61 (19.5) (1–3)	63 (20.1) (1–2)	111 (35.5) (1–5)
Upper respiratory tract	280	35 (11.8) (1–2)	46 (14.7) (1–2)	73 (23.3) (1–3)	89 (28.4) (1–4)
Gastrointestinal	120	6 (1.9) (1–1)	29 (9.3) (1–2)	43 (13.7) (1–4)	28 (8.9) (1–2)
Not an infection <sup>a</sup>	113	4 (1.3) (1–1)	15 (4.8) (1–1)	42 (13.4) (1–3)	37 (11.8) (1–4)
Eye	75	18 (5.8) (1–2)	11 (3.5) (1–2)	14 (4.5) (1–1)	23 (7.4) (1–2)
Unspecified febrile illness	56	3 (1) (1–1)	11 (3.5) (1–2)	16 (5.1) (1–2)	20 (6.4) (1–2)
Urinary tract and genital	36	8 (2.6) (1–1)	4 (1.3) (1–1)	9 (2.8) (1–1)	14 (4.5) (1–2)
Not stated <sup>b</sup>	27	5 (1.6) (1–1)	6 (1.9) (1–2)	5 (1.6) (1–1)	10 3.2) (1–1)
Neurological	13	2 (0.6) (1–1)	3 (1) (1–1)	3 (1) (1–2)	4 (1.3) (1–1)
Contacts	9	0	2 (0.6) (1–1)	4 (1.3) (1–1)	3 (1) (1–1)
Dental and oral disease	9	3 (1) (1–1)	1 (0.3) (1–1)	1 (0.3) (1–1)	4 (1.3) (1–1)
Fever and rash	8	2 (0.6) (1–1)	1 (0.3) (1–1)	4 (1.3) (1–1)	1 (0.3) (1–1)
Post-streptococcal disease	7	0	0	1 (0.3) (1–1)	6 (1.9) (1–1)
Bone and Joint	5	0	2 (0.6) (1–1)	2 (0.6) (1–1)	1 (0.3) (1–1)
Blood	5	3 (1) (1–1)	0	1 (0.3) (1–1)	1 (0.3) (1–1)

<sup>a</sup>Data reviewed by a physician and the reason given in file for the presentation was not an infection.

<sup>b</sup>Antibiotics prescribed but the reason for the prescription not stated.